Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
Open Access
- 10 August 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 103 (6), 845-851
- https://doi.org/10.1038/sj.bjc.6605831
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialBritish Journal of Cancer, 2010
- The dual role of thymidine phosphorylase in cancer development and chemotherapyMedicinal Research Reviews, 2009
- Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative ChemoradiotherapyClinical Cancer Research, 2008
- ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiationBritish Journal of Cancer, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Predictive Role of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Expression in Colorectal Cancer Patients Receiving Adjuvant 5-FluorouracilOncology, 2006
- Thymidine Phosphorylase (TP) Activation: Convenience Through InnovationThe Oncologist, 2001
- The Traveling Oncologist and the Wages of SinThe Oncologist, 2001